Results for "Understanding Pharmaceutical Distribution"
Distributors' Sustainability Efforts: Protecting Patients and the Planet
A new report estimates that the overall health costs of climate change already exceed $820 billion each year. The healthcare sector alone is responsible for nearly 5 percent of worldwide greenhouse gas emissions. According to a December 2020 Health Affairs study, “health damages stemming from U.S. [healthcare] pollution in 2013 [are] on the same order of magnitude as deaths from preventable medical errors.” Unfortunately, many of the most vulnerable communities are impacted by the harmful effects of climate change.
How Distributors Facilitate Patient Access to Specialty Therapies
Specialty pharmaceuticals — complex medications that require special handling, administration and ongoing clinical support — are reshaping healthcare delivery. These therapies offer hope for patients living with serious or chronic conditions; however, specialty medications are also introducing unprecedented complexity in how products are being manufactured, transported and accessed.
HDA Survey Results Indicate More Preparation Necessary for Connecting EPCIS-Enabled Systems Before DSCSA Deadline
Data released by the Healthcare Distribution Alliance (HDA) indicate more preparation is needed to ensure all healthcare supply chain partners are ready to meet the requirements of the Drug Supply Chain Security Act (DSCSA). HDA’s latest EPCIS Implementation Benchmarking Survey provides a final report on supply chain partners’ progress toward the November 27, 2023, deadline to connect data systems to exchange serialized transaction data for all pharmaceuticals.
HDA Statement on “Most-Favored-Nation” Executive Order
HDA released a statement in response to President Donald J. Trump’s Executive Order establishing a “Most-Favored-Nation” (MFN) pricing policy for pharmaceuticals.